BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

406.26 19.01 +4.91%
Market cap
$40.4B
P/E
68.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Sep '26 From the 10-Q filed 5 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
— 7 7 7

+8 more TTM periods

ROE
18.40% 14.66% 12.42% 7.46%
ROA
10.46% 8.47% 7.13% 4.07%
ROIC
85.21% 60.22% 46.03% 36.03%
Return on Tangible Assets
12.47% 9.73% 7.98% 4.75%
Average Days of Receivables
60.36 62.90 59.66 59.10
Free Cash Flow per Share
0.00 11.92 10.05 8.45
Free Cash Flow
1,449.25 1,330.19 1,114.61 921.74
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026